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Expression of Vascular Endothelial Growth Factor in PreImplantation Mouse Embryos 
Abstract 
Establishment of an adequate endometrial vascular supply is crucial for successful implantation 
and development of mammalian embryos. Uterine endometrial receptivity determines the success of 
implantation, as human embryos and gametes are routinely harvested, maintained and fertilized in vitro 
in assisted reproduction. Once a viable embryo is transferred to a uterus, however, its chance of 
establishing a pregnancy in the recipient female is only approximately 20%. Embryos placed in the 
distal portion of the fallopian tube typically show a higher rate of pregancy success, thus suggesting that 
embryo-derived factors may contribute to uterine receptivity. 
Angiogenesis, the extensive development and growth of capillaries, is essential to the 
establishment of the vascular network needed for maternal-fetal exchange through the placenta. Prior to 
implantation, the endometrial vascular network is random and contains no specific orientation. Factors 
released at the site of implantation cause the vessels to orient towards the developing embryo and 
provide it with an ample blood supply. The factor(s) that directs blood vessel formation during 
implantation is not known. 
Vascular endothelial growth factor (VEGF) is specific to vascular endothelial cells and has 
significant angiogenic and permeability effects. There are four main variants of VEGF that are due to 
alternative exon splicing of a single mRNA strand. Two variants are cell-associated (206 and 189), 
while two are soluble (165 and 121). There are no known functional differences between the variants. 
Receptors for VEGF areftns-Iike tyrosine kinase (flt) and kinase domain-containing receptor (KDR). 
They are predominantly expressed on endothelial cells, although the embryo may also contain receptors 
on its trophoblast cells. 
The purpose of this study was to determine if VEGF is expressed in the early preimplantation 
mouse embryo. The uterus is known to make VEGF but it was not known if the preimplantation embryo 
itself made VEGF or if it contained VEGF receptors. Mouse eggs and embryos were used because their 
embryonic implantation is similar to human implantation. The availability of samples and ethics 
concerns also made mouse specimens the viable choice. 
RNA was extracted from the eggs/embryos then made into a complementary strand of DNA 
(cDNA) by the process of reverse transcriptase. An oligo (dT) primer was used to differentiate mRNA 
being actively translated, which contained poly A + tails, from other mRNA in the sample. Once the 
cDNA was obtained, it was amplified by polymerase chain reaction (PCR). Mouse kidney cDNA was 
used for the positive control tissue as it was known to contain both VEGF and actin and was the same 
tissue type as the samples. Actin was used as the control gene within the sample because it is highly 
expressed in all cells. The primers used were expected to produce a 548 base pair fragment for actin, and 
a 349 base pair fragment for VEGF that is common to all VEGF variants. To test for contamination, a 
negative control containing only the stock reagents and ddH20 was also prepared. The PCR products 
were loaded into non-denaturing polyacrylamide gels for electrophoresis analysis. 
Both mouse eggs and blastocysts appear to express VEGF. It is difficult to envision a role for 
VEGF in the egg stage, but it may be involved in early folliculogenesis. VEGF, if secreted by the 
embryo, may flow down the fallopian tube and prime the uterus for implantation. When the blastocyst 
begins to implant, VEGF may promote blood vessel redirection and growth at the implantation site. At 
the blastocyst stage, VEGF may act as both a permeability and an angiogenic factor. A third function for 
VEGF may also exist at this stage. The blastocyst produces VEGF and the trophoblast cells are believed 
to contain VEGF receptors, therefore the blastocyst may induce its own growth. 
Introduction 
Establishment of an adequate endometrial vascular supply is crucial for successful 
implantation and development of mammalian embryos. Uterine endometrial receptivity 
determines the success of implantation, as human embryos and gametes are routinely harvested, 
maintained and fertilized in vitro in assisted reproduction. Once a viable embryo is transferred to 
a uterus, however, its chance of establishing a pregnancy in the recipient female is only 
approximately 20%. Embryos placed in the distal portion of the fallopian tube typically show a 
higher rate ofpregnancy success, thus suggesting that embryo-derived factors may contribute to 
uterine receptivity. 
Angiogenesis, the extensive development and growth of capillaries, is essential to the 
establishment of the vascular network needed for maternal-fetal exchange through the placenta. 
It differs from vasculogenesis in that angiogenic growth occurs from pre-existing cells and 
vessels rather than creating totally new ones. Prior to implantation, the endometrial vascular 
network is random and contains no specific orientation. Factors released at the site of 
implantation cause the vessels to orient towards the developing embryo and provide it with an 
ample blood supply (Torry R and Rongish B, 1992). The factor(s) that directs blood vessel 
formation during implantation is not known. 
Vascular endothelial growth factor (VEGF) is specific to vascular endothelial cells and 
has significant angiogenic and mitogenic effects (Ferrara N et a!., 1992). It has also been shown 
to increase microvascular permeability and was originally named vascular permeability factor 
(Brown Let a!., 1992). Preventing tumor angiogenesis has been the main focus of much recent 
research involving VEGF, as tumors cannot survive if their blood supply is ceased. The role of 
VEGF in reproduction is now being explored and its full involvement in that field is not yet 
known. 
There are four isoforms of VEGF that originate from alternative exon splicing of a single 
mRNA strand (Ferrara et aI., 1992). There are thought to be no functional differences between 
the four variants, but they do have significant biological differences. VEGF206 and VEGF 189 are 
cell-associated, meaning they only affect cells adjacent to cells that produce these variants. The 
other two isoforms, VEGF l65 and VEGFI21 , are diffusable into the extracellular matrix. Thus, the 
variant determines what cells VEGF acts on in relation to the cells that express it. If secreted by 
the embryo, VEGF could contribute to local permeability and angiogenesis and/or prime the 
uterus for implantation, depending on the variant( s) expressed. 
Receptors for VEGF are thefms-like tyrosine kinase (fit) and kinase domain-containing 
receptor (KDR). They are predominantly expressed on endothelial cells, although the embryo 
may also contain receptors on its trophoblast cells (Charnock-Jones D et aI., 1994, Torry D et al., 
unpublished). Since VEGF is known to have mitogenic effects, if embryos secrete VEGF and 
also contain receptors for it, they may use VEGF as a means to promote their own growth. 
The purpose of this study was to determine if VEGF is expressed in the early 
preimplantation mouse embryo. The uterus is known to make VEGF (Torry D et aI., 1995) but it 
was not known if the preimplantation embryo itself makes VEGF or if it contains VEGF 
receptors. Mouse eggs and embryos were used because their embryonic implantation is similar 
to human implantation. The ready availability of samples and ethical concerns also made mouse 
specimens the viable choice. 
Materials and Methods 
Mouse Kidney Samples 
A whole mouse kidney was surgically removed from a sacrificed mouse and snap-frozen 
in liquid nitrogen immediately upon removal. The kidney was stored at -80°C until used. GITC 
solution was added and the kidney was ground with a tissue homogenizer. RNA was extracted 
via the GITC method (see below). 
MCF-7 Breast Cancer Cells 
A T25 flask was grown to confluency and RNA was extracted via the GITC method 
(see below). 
Mouse Embryo Samples 
The embryos used in these studies were collected at different stages ofpreimplantation 
development (Hogan, et aI., 1986). Egg samples were collected by first priming the mice with 
SID pregnant mare serum gonadotropin (PMSG). After 48 hours they were given human 
chorionic gonadotropin (hCG) to induce superovulation. The oviducts were flushed with Hams 
FlO culture media containing 1 % Human Serum Albumin (HSA) 12 hours later to collect the 
free eggs. Cumulus cells were removed by hyuronidase (lmg/10mL). Typically a final volume 
of 2 microliters (J.1L) of media contained 10 eggs. 
More advanced stages of embryonic development were collected after in vitro culturing 
of fertilized eggs. The mice were induced to superovulate with SID of PMSG followed 48 hours 
later with SID hCG. They were then placed in cages with proven fertile mates. The females 
were sacrificed at day 1.5 post coitus (d 1.5 p.c.) and their oviducts were flushed to collect the 
embryos at the 2 cell stage. A portion of the embryos were cultured under standard conditions 
and samples were collected at the zona pellucida-free late blastocyst stage (d4.5 p.c.). The late 
blastocyst stage corresponds to the time of implantation in vivo in mice. The GITC method was 
predominantly used to extract RNA (see below), however the crude lysate method (see below) 
was used when GITC failed to obtain enough RNA for amplification. 
Extraction ofRibonucleic Acid (RNA) by the Guanidinium Isothiocynate (GITC) Method 
To extract RNA from the samples, the cells were first lysed (Chomczynski and Sacchi, 
1987). A lysing stock solution was made of 4M GITC (83.3g), 25 mM Na Citrate (pH=7, 
5.87mL of .75M), 0.5% N-Iauroylsarcosine (8.8mL of 10%), and 97.67 mL 
diethylpyrocarbonate treated water (DEPC H20). This stock solution was combined with 
2-~-mercaptoethanol (2-ME) in the following ratio to create a working solution: 14 J.lL 2-ME to 
2mL of stock solution. 500J.lL of the working solution was added to the cell sample and the cells 
were lysed on ice for 15 minutes. 
After denaturization occurred, RNA was extracted from the eggs/embryos. The following 
reagents were added in order on ice for 500J.lL of denaturing solution: 50J.lL 2M Na-acetate 
(PH=4.0), 500J.lL phenol (H20 saturated, not buffered), and 100J.lL chloroformlisoamylalcohol 
(24:1). The solution was mixed and kept on ice for 15 minutes, then centrifuged at 10,000 x g 
for 20 minutes. The aqueous phase of the solution was removed and ImL of isopropanol was 
added. The RNA was placed at -20°C to -80°C and allowed to precipitate overnight. The 
precipitated solution was centrifuged at 10,000 x g for 20 minutes and the supernatants were 
removed. The pellet was resuspended in 300J.lL GITC/2-ME (working solution) and 300J.lL 
isopropanol was added. The solution was allowed to re-precipitate at -20°C to 80°C for at least 
30 minutes. The precipitated solution was centrifuged at 10,000 x g for 15 minutes and the 
supernatants were removed. The pellet was washed with 500flL 75% ethanollDEPC H20 
solution and centrifuged. The supernatants were again removed. The pellet was dried under 
vacuum and then resuspended in DEPC H20 and IOU of RNa sin. The optical density at 260 
nanometers was taken to determine the RNA concentration of the solution according to the 
formula: absorbance of 1.0 = 30flg/mL RNA. 
Preparation ofRNA Using the Crude Lysate Method 
In this method, all reactions took place in the crude lysates to avoid loss of RNA during 
the purification process (Pal et al., 1994). Snap-frozen eggs/embryos were lysed by adding an 
equal volume of 0.5% Nonidet-P 40 (NP-40), 10mM dithiothreitol (DTT), and IOU Rnasin. The 
solution was reverse transcribed (see below) and run through a spin column to concentrate the 
RNA and DNA. It was then dried under a vacuum, resuspended in 20flL double distilled water 
(ddH20), and heated at 50°C to 60°C for 10 minutes. 
Synthesis ofComplementary Deoxyribonucleic Acid (cDNA) by Reverse Transcriptase (RT) 
Reaction 
IOflg of RNA (usually in <5flL) were mixed with 10 pmol of oligo (dT)18 in a 0.5flL 
RNA-safe Eppendorftube. The primer oligo (dT)18 was used to differentiate messenger RNA 
(mRNA) being actively translated, which contain poly A+ tails, from non-translated mRNA. 
The mixture was placed at 70°C for 2 minutes in a water bath and then slow cooled to 35°C. A 
reverse transcriptase reagent mix consisting of 20U avian myeloblastosis virus reverse 
transcriptase (AMV-RT), 4flL 5x AMV-RT buffer, IflL of each 10mM deoxyribonucleotide 
triphosphate (A,C,G,T), 0.2flL 1M DTT, and 14U RNasin, was added to the RNA and 
oligo(dT)]8' DEPC H20 was added to the mixture to make the final volume of the RT reaction 
equaI20J..lL. The entire mixture was incubated at 42°C for two hours and then was placed for 2 
minutes at 95°C to inactivate the RT. Afterwards it was chilled on ice for 1 minute and 
centrifuged at maximum for a few seconds. The newly prepared cDNA was kept frozen and 
stored at -20°C. 
Amplification ofGenes Present in cDNA Sample by Polymerase Chain Reaction (PCR) 
Under an isolation hood, a working stock solution of PCR reagents was prepared 
proportionally to the number of samples tested. For each sample tube, 5 J..lL lOx PCR Buffer 1, 
IJ..lL of each 10mM deoxribonucleotide triphosphate (A,C,G,T), 1 flL sense primer (100 pmol), 
1 flL anti-sense primer (100 pmol), and 2.5U AmpliTaq® DNA Polymerase were added. The 
primers for each gene were: 
Actin sense 5 '-CTC-CTT-AAT-GTC-ACG-CAC-GAT-TTC-3 , 
Actin anti-sense 5'-GTG-GGG-CGC-CCC-AGG-CAC-CA-3' 
VEGF sense 5 '-ATG-AAC-TTT-CTG-CTG-TCT-TGG-T-3 , 
VEGF anti-sense 5'-CTC-ATC-TCT-CCT-ATG-TGC-3' 
These primers were expected to produce a 548 base pair fragment for actin and a 349 base pair 
fragment for VEGF that is common to all VEGF isoforms. 
Aliquots of 11.5flL of the stock solution were put into each PCR tube. 5J..lL of cDNA and 
33.5J..lL ddH20 were added to the solution to make the final volume equal 50flL. In some cases 
the amount of cDNA assayed was increased to raise sensitivity. Mouse kidney cDNA was used 
for the positive control as it is known to contain both VEGF and actin (Brown et al., 1992). To 
test for contamination, a negative control containing only the stock solution and 38.5~L ddH20 
was also prepared. 55JlL of mineral oil was added to each sample tube and one drop ofmineral 
oil was placed into the wells of a Perkin-Elmer Model PCR thermal cycler. The tubes were 
seated into the wells and the machine was set for 35 cycles for 1 minute each at 94°C, 61 °c, and 
72°C. At the end of the cycles, the samples stayed at 72°C for 5 minutes and then went to a 4°C 
hold until their removal. They were stored at -20°C until analyzed by gel electrophoresis. In 
some cases heightened sensitivity was needed so a "nested PCR" was performed. Instead of 
cDNA, I~L ofPCR product was added to 11.5JlL of stock solution and 37.5~L ddH20. The 
tube was then placed in the thermal cycler and the machine was set for 25 cycles of the same 
temperatures and durations as above. 
Analyses ofpeR Products by Non-Denaturing Polyacrylamide Gel Electrophoresis 
A 50/0 non-denaturing acrylamide gel solution was prepared using 2.0 mL 40% Acryl­
Bisacryl, 1.6 mL lOx Tris (Hydroxymethyl) Aminomethane-Borate-Ethylenediaminetetraacetic 
acid buffer (TBE), 12.4 mL ddH20, 20 JlL Tetramethyl-ethylenediamine (TEMED), and 100 J.1L 
10% NH4S02 • The solution was gently mixed so as not to introduce air bubbles and was poured 
between two glass plates enclosed in a gel caster. A comb was placed at the top of the plates to 
form wells for the samples. When solidified, the gel and the glass plates were removed from the 
caster and clamped onto an electrophoresis unit. 1 x TBE buffer was added to the top chamber 
until it spilled over into the sample wells (~ 150 mL). 1 x TBE buffer was also added to the 
bottom tank chamber until it was approximately half full (~ 250 mL). 
5~L of DNA sample loading buffer was added to 20~L aliquots of the PCR products and 
to a 0.7 JlL aliquot of 123 base pair ladder molecular weight marker. The samples were loaded 
into the sample wells using a long-nosed pipette tip. 
The electrodes were attached to the electrophoresis unit and 100 volts of electricity was 
applied until the bromophenol blue in the loading buffer ran off the bottom of the gel. The glass 
plates containing the gel were unclamped from the unit and carefully pried apart. The gel and the 
remaining glass plate were placed in a gel staining tray containing ddH20. The water released 
the gel from the plate and the plate was removed. 3 JlL ethidium bromide (EtBr) was added to 
the water. The gel was allowed to soak in the EtBr solution for 10 minutes with slow agitation to 
stain the DNA bands on the gel for interpretation under UV light. For band clarity, the gel was 
destained by draining the EtBr solution from the tray and adding fresh ddH20. The gel was then 
photographed under UV light with a Polaroid MP-4 photography set using type 57 film. 
Results 
Expression of VEGF in MCF-7 Cells and Mouse Kidney 
Preliminary tests were conducted on non-precious samples to test procedures and primers. 
MCF -7 breast cancer cells show an overexpression of VEGF, as cancerous cells typically do 
(Boocock C et aI., 1995). Since determining VEGF expression in a normal tissue was ultimately 
the goal of these tests, mouse kidney was used as a comparison to the MCF -7 cells. 
RNA was extracted via the GITC method and stored at -80°C until analyzed by RT-PCR. 
The RNA concentration was 1.6 Jlg/JlL for MCF-7 and 4.2 Jlg/JlL for mouse kidney. 10Jlg of 
RNA from each sample were reverse transcribed to produce 20JlL of cDNA. For PCR, 2.5JlL of 
cDNA were taken from the MCF-7 sample to test for actin, and 5JlL ofcDNA were taken to test 
for VEGF. The amounts of cDNA taken to test for actin and VEGF were the same for the mouse 
kidney. 
Through the use of non-denaturing polyacrylamide gel electrophoresis, the number of 
base pairs in a sample were gauged against a 123 bp ladder molecular weight marker. In Fig. 1, 
actin in MCF-7 cells produced a strong band at the predicted 548 bp level (lane 2). Mouse 
kidney also expressed actin, as its band can clearly be seen at that level in lane 3. The expression. 
of actin in these two samples shows that the RNA extraction, RT, and peR procedures were 
successful and thus gives credence to the VEGF lanes. A 349 bp fragment, the size predicted for 
VEGF, was detected for MCF-7 in lane 6 and for mouse kidney in lane 7. Both negative control 
lanes were blank (lanes 4 and 8), indicating no contamination was present. 
Expression of VEGF in Mouse Eggs, Cumulus Cells, Blastocysts, and Mouse Kidney 
After several unsuccessful attempts to isolate an adequate amount of RNA from eggs 
using the GITC method, it was determined that another method might yield more RNA. The 
crude lysate method was then used to prepare RNA from 19 mouse eggs. IOU RNasin and IOflL 
of the NP-40IDTT mix were added to the eggs to lyse them. After reverse transcription, 80flL of 
cDNA were obtained from the eggs. 50JlL were removed and run through a spin column, dried 
under a vacuum, and resuspended in 20JlL ddH20. For PCR, 10JlL of the concentrated cDNA 
were used to test for actin, while the other 10JlL were used to test for the presence ofVEGF. In 
order to increase sensitivity, a nested PCR was also performed for both actin and VEGF using 
1flL of their respective PCR products to serve as a substitute for cDNA. 
The RNA from cumulus cells, blastocysts, and kidney tissue were extracted using the 
GITC method. The RNA concentration was 11.1 Jlg/JlL for cumulus cells, 2.3 flg/flL for 
blastocysts, and 4.2flg/JlL for the mouse kidney. lOJlg of RNA from each sample were reverse 
transcribed, producing 20flL of cDNA from each of them. 5JlL ofboth blastocyst cDNA and 
cumulus cell cDNA were removed to test for actin. The same volume of each was also removed 
to test for the presence ofVEGF. From the kidney cDNA, 2flL were removed to test for actin, 
while 4JlL were removed to test for VEGF. Negative controls lacking cDNA were also prepared. 
All of these samples produced a final PCR product volume of 50JlL after stock solutions and 
primers were added. 
The PCR products were analyzed by gel electrophoresis. The RT-PCR process 
succeeded, as fig. 2 shows a 548 bp fragment of actin in the egg (lane 1), nested egg (lane 2), 
blastocyst (lane 4), and mouse kidney (lane 7). However, it was not seen in cumulus cells (lane 
4). VEGF appears to be expressed throughout embryonic development, as Fig. 3 shows the 
predicted 349 bp fragment ofVEGF in the egg (lane 2), nested egg (lane 3), cumulus cells (lane 
4) blastocysts (lane 5) and mouse kidney (lane 7). The negative controls (lane 6 in figs. 2 and 
3) were both blank indicating no contamination was present. 
mw M K C mw M K C 
Actin 
~VEGF 
Fig. 1. Expression of actin and VEGF analyzed by RT-PCR. Ethidium bromide stained po1yacryJamide gel 
showing actin in MCF-7 cells (lane 2), actin in mouse kidney (lane 3) VEGF in MCF-7 cells (lane6), VEGF in 
mouse kidney (lane 7) and controls (no cDNA added lanes 4 and 8). Molecular weight markers (MW) are a 123 
bp ladder. Sizes predicted for actin and VEGF were 548 and 349 bp respectively. 
mw E NE Cu B C K 

~Actin 
Fig. 2. Expression of actin analyzed by RT-PCR. Ethidium bromide stained polyacrylamide gel showing actin in 
eggs (lane 2), nested eggs (lane 3), blastocysts (lane 5), and mouse kidney (lane 7). No actin is evident in cumulus 
cells (lane 4). The control (no cDNA added, lane 6) is negative for contamination. The molecular weight marker 
(MW) is a 123 bp ladder. The predicted actin size was 548 bp. 
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Fig. 3. Expression of VEGF analyzed by RT-PCR. Ethidium bromide stained polyacrylamide gel showing 
YEGF in eggs (lane 2), nested eggs (lane 3), cumulus cells (lane 4), blastocysts (lane 5), and mouse kidney (lane 7). 
The control (no cDNA added, lane 6) is negative for contamination . The molecular weight marker (MW) is a 123 
bp ladder. The predicted YEGF size was 349 bp. 
Discussion 
By RT-PCR analysis, both mouse eggs and blastocysts appear to express VEGF. Since 
the VEGF fragment produced by PCR is common to all four variants, it is impossible to 
differentiate which variant(s) is being produced. Since cumulus cells are known to express 
VEGF (fig. IB, Kamat Bet aI.., 1995), egg samples that are not totally cumulus-free may appear 
to express VEGF when none is actually present. The egg samples tested in this study, however, 
were visibly free of any cumulus cells. The crude lysate method ofpreparing the egg RNA may 
also have contributed to the appearance of a VEGF band. The egg cDNA that was used was 
heavily concentrated and PCR may have amplified a miniscule amount of VEGF message that is 
not biologically relevant. It is believed, based on this study, that VEGF is expressed in the egg 
although its role at that stage is not yet understood. One possibility for VEGF involvement at the 
egg stage is in folliculogenesis. Future studies could compare equal volumes of cumulus-free 
egg samples with cumulus-attached egg samples to determine the validity of VEGF expression. 
At the blastocyst stage, VEGF may be important in implantation by initiating 
reorientation of blood vessels and increasing vascular permeability. VEGF variants 121 and 165 
are soluble and, if present in the embryo, could precede it and prime the uterus for implantation. 
VEGF variants 189 and 206, if present, may influence local permeability and angiogenic events 
at the implantation site. Therefore, VEGF may be necessary for successful implantation of the 
embryo and for placental growth. Future studies could test for the individual variants of VEGF 
in the blastocyst to determine which one(s) is expressed. 
A possible additional function of VEGF besides angiogenesis and permeability may be 
trophoblast growth promotion. Since trop~oblast cells are believed to contain VEGF receptors 
(Charnock-Jones D et al., 1994, Torry D et al., unpublished) and the blastocyst was shown to 
produce VEGF, the blastocyst may induce its own trophoblast growth. 
The major source of VEGF within the blastocyst is not known, but it is likely to be the 
trophoblast. Therefore, trophoblast production of VEGF could induce trophoblast receptors and 
possibly promote both placental formation and trophoblast growth. In future studies, trophoblast 
cells could be separated from the inner cell mass and tested individually for VEGF expression. 
This would determine the exact location of VEGF secretion from the blastocyst. 
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